Drug Discovery

Neurogeneration has established a highly-focused drug discovery platform built on the company’s deep knowledge of inhibitors and inflammatory events as causative factors of synaptic damages triggered by soluble ABeta oligomers  accumulation

Neurogeneration selective novel small molecules therapy may become  a new treatment for progressive neurodegenerative changes at the synaptic and intra-neuronal levels.  Its pharmacokinetic profiles is being optimized to drive a robust therapeutic response in various pre-clinical models and aging disorders prior to its use in clinical trials.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s